Avantor, Inc.
NYSE•AVTR
CEO: Mr. Michael Stubblefield
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2019-05-17
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Contact Information
Radnor Corporate Center, Building One Suite 200 100 Matsonford Road, Radnor, PA, 19087, United States
610-386-1700
Market Cap
$6.23B
P/E (TTM)
-11.2
55.3
Dividend Yield
--
52W High
$15.93
52W Low
$7.27
52W Range
Rank45Top 56.8%
3.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$1.58B+0.00%
4-Quarter Trend
EPS
$0.06+0.00%
4-Quarter Trend
FCF
$25.20M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Net Sales Decline 3.4% Net sales totaled $6,552.2M USD, down 3.4% from prior year; organic sales decreased 2.8% USD.
Goodwill Impairment Recorded Recorded $785.0M non-cash goodwill impairment charge in Q3 2025 impacting Distribution reporting unit valuation.
Strong Liquidity Position Maintained Total liquidity reached $1,745.9M USD at year-end, supported by $1,380.5M unused credit facility availability.
Share Repurchase Authorization Board authorized $500.0M common stock repurchase program in October 2025; $75.0M executed in Q4 2025.
Risk Factors
Operating Results Deterioration Operating loss reached $(246.2)M USD, a $1,331.0M decline, driven by impairment and lower gross profit.
Supply Chain Inflation Pressures Experienced inflationary pressures across cost categories; pricing and productivity measures may not fully offset adverse impact.
Customer Demand Slowdown Laboratory Solutions sales declined due to reduced demand for consumables and increased competitive intensity in end markets.
Regulatory Compliance Exposure Subject to complex and evolving global laws regarding data privacy, trade, and environmental compliance; failure risks material impact.
Outlook
Cost Transformation Initiative Expanded Cost transformation initiative expanded; now targeting $400M in run rate gross savings by the end of 2027.
Future Segment Realignment Planned Intends to implement new operating model effective January 1, 2026, with two segments: VWR Distribution & Services.
Focus on Innovation Model Continue investing in differentiated innovation model, enhancing product purity and developing new products in cell and gene therapy.
No Cash Dividends Expected Currently do not expect to pay cash dividends on common stock due to debt agreements limiting distributions.
Peer Comparison
Revenue (TTM)
$45.08B
$13.38B
$11.32B
Gross Margin (Latest Quarter)
62.1%
52.3%
50.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ESI | $10.34B | 69.4 | 5.6% | 37.6% |
| BAX | $9.70B | -8.8 | -16.4% | 48.8% |
| MASI | $9.34B | 122.1 | 9.1% | 29.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.1%
Flat Growth
4Q Net Income CAGR
-12.5%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Aug 7, 2026
EPS:$0.19
|Revenue:$1.61B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data